BELLUS Health Inc. (BELLUS Health), is a development-focused healthcare company. BELLUS Health is focusing on products, which provides health solutions and address medical needs. The Company�s product portfolio includes two pharmaceutical drug candidates and one commercial stage nutraceutical product, which include KIACTA, BLU8499 and VIVIMIND. BELLUS Health� primary focus is on advancing KIACTA, a treatment for AA amyloidosis through a pivotal Phase III Confirmatory Study. In August 2013, BELLUS Health Inc. acquired Thallion Pharmaceuticals Inc.